MSH Release-Inhibiting Hormone (MIF-I)

A hypothalamic tripeptide, enzymatic degradation product of OXYTOCIN, that inhibits the release of MELANOCYTE-STIMULATING HORMONES.

Also Known As:

MIF-I; H-Pro-Leu-Gly-NH2; MIF-1; Melanocyte-Stimulating Hormone Release-Inhibiting Factor; Melanostatin; Oxytocin (7-9); Pro-Leu-Gly-NH2; Pro-Leu-Glyamide; Prol-Leu-Gly-NH2; Prolylleucylglycinamide; Prol Leu Gly NH2; Prolyl Leucyl Glycinamide; MSH Release-Inhibiting Factor; Melanocyte-Stimulating Hormone Release-Inhibiting Hormone; Prolyl-Leucyl-Glycinamide

Networked: 54 relevant articles (3 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Mishra, Ram K: 3 articles (01/2018 - 01/2003)
2.	Hsuchou, Hung: 2 articles (01/2010 - 07/2009)
3.	Kastin, Abba J: 2 articles (01/2010 - 07/2009)
4.	Pan, Weihong: 2 articles (01/2010 - 07/2009)
5.	Yu, Chuanhui: 2 articles (01/2010 - 07/2009)
6.	Benedek, Gil: 1 article (01/2022)
7.	Bucala, Richard: 1 article (01/2022)
8.	Gerstner, Grant: 1 article (01/2022)
9.	Kent, Gail: 1 article (01/2022)
10.	Meza-Romero, Roberto: 1 article (01/2022)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2010 - "MIF-1 (Pro-Leu-Gly-NH(2)) is a tripeptide for which the therapeutic potential in Parkinson's disease and depression has been indicated by many studies. " 02/01/1978 - "[Physiological trials with MIF-I in Parkinson's disease (author's transl)]." 07/01/1976 - "[MIF (melanocyte-stimulating hormone release-inhibiting factor) and Parkinson's disease]." 01/01/2003 - "Central dopaminergic systems are implicated in schizophrenia and Parkinson's disease, and are known to be modulated by the endogenous tripeptide Pro-Leu-Gly-NH(2) (PLG or MIF-1, melanocyte-stimulating hormone release inhibiting factor-1). " 01/01/2010 - "The cellular activation in specific brain regions illustrates the biochemical and neuroanatomical basis underlying the therapeutic effect of MIF-1 in Parkinson's disease and depression."
2.	Tardive Dyskinesia 07/01/1980 - "MSH and MIF-I in animal models of tardive dyskinesia." 05/01/1990 - "MIF-1 has been reported to potentiate the melanocyte-lightening effect of melatonin in rats and its effects in patients with Parkinson's disease and Tardive dyskinesia are associated with marked mood elevation. " 05/01/1990 - "There is evidence to suggest that MIF-1 increases nigro-striatal dopaminergic activity, but its ability to improve symptoms in patients with Parkinson's disease, levodopa-related dyskinesias and Tardive dyskinesia cannot be explained solely on the basis of the drug's effect on striatal dopaminergic neurons. " 05/01/1990 - "MIF-1, a synthetic tripeptide with MSH-release inhibitory properties, has been reported to improve symptoms of Parkinson's disease, attenuate levodopa-related dyskinesias and diminish the dyskinetic movements of Tardive dyskinesia. " 04/01/1984 - "These studies suggest that the hypothalamic peptide, Pro-Leu-Gly-NH2 and its long-acting analog, cyclo (Leu-Gly) can prevent the development of both behavioral and biochemical supersensitivity of dopamine receptors in brain induced by neuroleptic drugs and that these peptides may be useful in preventing the development of neuroleptic-induced tardive dyskinesia."
3.	Dyskinesias (Dyskinesia) 05/01/1990 - "There is evidence to suggest that MIF-1 increases nigro-striatal dopaminergic activity, but its ability to improve symptoms in patients with Parkinson's disease, levodopa-related dyskinesias and Tardive dyskinesia cannot be explained solely on the basis of the drug's effect on striatal dopaminergic neurons. " 05/01/1990 - "MIF-1, a synthetic tripeptide with MSH-release inhibitory properties, has been reported to improve symptoms of Parkinson's disease, attenuate levodopa-related dyskinesias and diminish the dyskinetic movements of Tardive dyskinesia. "
4.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/2022 - "In the murine model of MS, experimental autoimmune encephalomyelitis (EAE), both male and female mice lacking MIF-1 and/or MIF-2 were clinically improved during development of moderately severe disease, thus implicating both homologs as co-pathogenic contributors. "
5.	Depressive Disorder (Melancholia) 05/01/1978 - "Five of 8 patients with unipolar or bipolar endogenous depressions taking prolyl-leucyl-glycinamide (MIF-I), 75 mg/day, showed substantial improvement within a few days of beginning treatment compared with similar improvement in only 1 of 10 receiving 750 mg/day of MIF-I and only 1 of 5 patients taking placebo. "

Related Drugs and Biologics

1.	MSH Release-Inhibiting Hormone (MIF-I)
2.	Melanocyte-Stimulating Hormones (MSH)
3.	Levodopa (L Dopa)
4.	Dopamine (Intropin)
5.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
6.	Peptides (Polypeptides)
7.	Naloxone (Narcan)
8.	tyrosyl-prolyl-leucyl-glycinamide
9.	Thyrotropin-Releasing Hormone (Protirelin)
10.	Oxotremorine

Related Therapies and Procedures

1.	Analgesia